Literature DB >> 2529815

Teicoplanin in the treatment of gram-positive-bacterial endocarditis.

P Martino1, M Venditti, A Micozzi, C Brandimarte, G Gentile, C Santini, P Serra.   

Abstract

Intravenous teicoplanin has been used to treat 23 cases of gram-positive-bacterial endocarditis, usually with 3 to 7 mg/kg every 12 h on the first day, followed by 3 to 7 mg/kg every 24 h. For some cases (staphylococcal and enterococcal endocarditis), the dosage was 8 to 14.4 mg/kg per day and/or other antibiotics were given. The mean duration was 48.2 days (range, 23 to 130 days). Of 23 patients, 21 (91.3%) had negative cultures or were cured. A total of 18 patients were treated with teicoplanin alone; of these, 4 had surgery, and all (except 2 who relapsed) were cured. Teicoplanin was combined with one or more antibiotics in five cases; in all cases appropriate cultures were negative, but three patients died during therapy or follow-up. Mild renal impairment was seen in two patients; both were receiving teicoplanin in combination with an aminoglycoside. We conclude that intravenous teicoplanin administered once a day at doses of 7 to 14 mg/kg per day is well tolerated, easy to administer, and may represent an efficacious therapy for gram-positive-bacterial endocarditis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2529815      PMCID: PMC172649          DOI: 10.1128/AAC.33.8.1329

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Comparison of the solid phase enzyme receptor assay (SPERA) and the microbiological assay for teicoplanin.

Authors:  L Cavenaghi; A Corti; G Cassani
Journal:  J Hosp Infect       Date:  1986-03       Impact factor: 3.926

2.  In vitro activity and human pharmacokinetics of teicoplanin.

Authors:  L Verbist; B Tjandramaga; B Hendrickx; A Van Hecken; P Van Melle; R Verbesselt; J Verhaegen; P J De Schepper
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

3.  Changing pattern of infective endocarditis.

Authors:  D Kaye
Journal:  Am J Med       Date:  1985-06-28       Impact factor: 4.965

4.  Teicoplanin versus nafcillin and vancomycin in the treatment of experimental endocarditis caused by methicillin-susceptible or -resistant Staphylococcus aureus.

Authors:  H F Chambers; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

5.  Right-sided valvular endocarditis: etiology, diagnosis, and an approach to therapy.

Authors:  M J Robbins; R Soeiro; W H Frishman; J A Strom
Journal:  Am Heart J       Date:  1986-01       Impact factor: 4.749

6.  In vitro activity of teichomycin and vancomycin alone and in combination with rifampin.

Authors:  P E Varaldo; E Debbia; G C Schito
Journal:  Antimicrob Agents Chemother       Date:  1983-03       Impact factor: 5.191

7.  Comparative in vitro activities of teichomycin and other antibiotics against JK diphtheroids.

Authors:  L Jadeja; V Fainstein; B LeBlanc; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

8.  Therapeutic efficacy of teicoplanin in experimental enterococcal endocarditis.

Authors:  P M Sullam; M G Täuber; C J Hackbarth; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1985-01       Impact factor: 5.191

Review 9.  Treatment of streptococcal infective endocarditis.

Authors:  W R Wilson; J E Geraci
Journal:  Am J Med       Date:  1985-06-28       Impact factor: 4.965

10.  Multicenter collaborative evaluation of a standardized serum bactericidal test as a prognostic indicator in infective endocarditis.

Authors:  M P Weinstein; C W Stratton; A Ackley; H B Hawley; P A Robinson; B D Fisher; D V Alcid; D S Stephens; L B Reller
Journal:  Am J Med       Date:  1985-02       Impact factor: 4.965

View more
  20 in total

Review 1.  Screening and treatment of infections caused by resistant enterococci.

Authors:  D J Herman; D N Gerding
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

2.  Antimicrobial susceptibilities of Erysipelothrix rhusiopathiae.

Authors:  M Venditti; V Gelfusa; A Tarasi; C Brandimarte; P Serra
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

3.  Treatment failure with teicoplanin and response to oral antibiotic regimens.

Authors:  P H McWhinney
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-06       Impact factor: 3.267

4.  Efficacy of teicoplanin-gentamicin given once a day on the basis of pharmacokinetics in humans for treatment of enterococcal experimental endocarditis.

Authors:  P López; J Gavaldà; M T Martin; B Almirante; X Gomis; C Azuaje; N Borrell; L Pou; V Falcó; C Pigrau; A Pahissa
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

Review 5.  Anti-gram-positive agents. What we have and what we would like.

Authors:  R N Grüneberg
Journal:  Drugs       Date:  1997       Impact factor: 9.546

6.  Inhibition of endotoxin-induced interleukin 8 release by teicoplanin in human whole blood.

Authors:  A Focà; G Matera; M C Berlinghieri
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-12       Impact factor: 3.267

7.  4-week treatment of streptococcal native valve endocarditis with high-dose teicoplanin.

Authors:  M Venditti; V Gelfusa; P Serra; C Brandimarte; A Micozzi; P Martino
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

Review 8.  Teicoplanin: 10 years of clinical experience.

Authors:  M Trautmann; H Wiedeck; M Ruhnke; M Oethinger; R Marre
Journal:  Infection       Date:  1994 Nov-Dec       Impact factor: 3.553

Review 9.  Recognition, management and prophylaxis of endocarditis.

Authors:  D Stamboulian; E Carbone
Journal:  Drugs       Date:  1997-11       Impact factor: 9.546

10.  Right-sided endocarditis caused by Staphylococcus aureus in drug abusers.

Authors:  J Fortún; J A Pérez-Molina; M T Añón; J Martínez-Beltrán; E Loza; A Guerrero
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.